Tesamorelin: A Complete Research Reference

Tesamorelin is a synthetic, stabilized GHRH analog approved as Egrifta for HIV-associated visceral fat. This guide covers the real trial evidence for visceral fat, liver fat, and cognition, how it differs from CJC-1295 and from GH itself, the approved and studied doses, and how the peptide-research community discusses it, with research-use-only framing throughout.

tesamorelin is a synthetic, stabilized copy of growth-hormone-releasing hormone (GHRH). It tells your pituitary to make and release more of your own growth hormone, which then raises IGF-1. It is FDA-approved as Egrifta for one narrow use: reducing excess visceral belly fat in HIV-associated lipodystrophy.

What Tesamorelin Actually Is

Tesamorelin is a stabilized analog of human GHRH (the 1-44 sequence). It binds the GHRH receptor on the anterior pituitary and prompts the synthesis and pulsatile release of your own growth hormone, which raises circulating IGF-1. That mechanism is well established in the endocrine literature PMID: 21668043PMID: 23657561.

The "stabilized" part matters. Native GHRH gets chewed up fast by enzymes. Tesamorelin carries an added N-terminal modification that slows that degradation and extends the half-life enough to make once-daily dosing practical PMID: 21668043.

Because it works one step upstream of the pituitary, tesamorelin keeps your body's own feedback loop intact. Somatostatin can still throttle GH when levels get high, so you get a pulse that looks closer to natural physiology than a flat exogenous dose would. In the pivotal HIV trials, 2 mg/day raised mean IGF-1 by roughly 81-108% while keeping it within or near the physiologic range PMID: 18057338PMID: 20554713.

The Visceral Fat Evidence (The Approved Use)

This is the part with real human RCT data behind it. Egrifta is approved specifically to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, and that approval rests on solid phase 3 work.

In the pivotal NEJM trial, 412 HIV patients with abdominal fat accumulation got 2 mg subcutaneously daily or placebo for 26 weeks. Visceral adipose tissue (VAT) dropped 15.2% on tesamorelin versus a 5.0% rise on placebo, triglycerides fell about 50 mg/dL, the total-cholesterol/HDL ratio improved, and IGF-1 rose 81% PMID: 18057338. A pooled analysis of two phase 3 trials (806 patients) put the treatment effect at -15.4% VAT at week 26, with lipids and body image improving and subcutaneous fat preserved PMID: 20554713.

Two findings stand out for anyone trying to understand this compound honestly. First, the benefit tracks with the fat loss: patients who lost more visceral fat (>=8% responders) had better triglyceride, adiponectin, and glucose outcomes than non-responders PMID: 22495074. Second, and this is the one people skip, the effect is not permanent. When tesamorelin was stopped, visceral fat re-accumulated PMID: 18690162. It behaves like a maintenance therapy, not a one-time reset.

There is also a liver-fat signal. In an RCT of 61 people with HIV and non-alcoholic fatty liver disease, 2 mg/day for 12 months cut hepatic fat fraction by about 37% relative, and 35% of the tesamorelin group reached a liver fat below 5% versus 4% on placebo, with no glucose worsening between groups PMID: 31611038.

The Cognition and Aging Signal

There is genuine human research here, and it is more interesting than most peptide "nootropic" claims, but it is early. A randomized, double-blind, placebo-controlled trial gave 152 older adults (ages 55-87, 66 with mild cognitive impairment) tesamorelin 1 mg/day for 20 weeks. GHRH favorably affected cognition (intent-to-treat P=.03, completers P=.002), with the benefit landing on executive function and a verbal-memory trend, in both healthy older adults and the MCI group. IGF-1 rose 117% and body fat dropped 7.4% PMID: 22869065.

A magnetic-resonance-spectroscopy substudy of 30 of those participants gives a plausible mechanism. Twenty weeks of tesamorelin raised brain GABA across three regions, raised NAAG in the frontal cortex, and lowered myo-inositol (an Alzheimer-linked osmolyte) in the posterior cingulate. The change in IGF-1 correlated with the change in GABA, which is early human evidence that GHRH nudges inhibitory neurotransmitters PMID: 23689947. A separate exploratory analysis of the same trial found neuronal exosome biomarkers (synaptophysin, synaptotagmin) could moderately distinguish treated from placebo MCI patients, though that is a biomarker hint, not proof of clinical benefit PMID: 30372675.

Read this signal for what it is: small trials, 20 weeks, promising, not established. It is not approved, and it does not show tesamorelin prevents or treats dementia.

Tesamorelin vs CJC-1295 vs GH

People constantly confuse these three. Here is the clean version.

The key line: tesamorelin and CJC-1295 are both GHRH analogs, same receptor, same "stimulate the pituitary" logic. Tesamorelin is the only GHRH analog with FDA approval and human RCT efficacy data. CJC-1295 has neither. GH is a different category entirely, because it is the hormone itself and it overrides the feedback system that tesamorelin and CJC-1295 leave in place.

How It Is Dosed: Studied Doses and Community Practice

Reported as fact: the FDA-approved Egrifta dose for HIV-associated lipodystrophy is 2 mg subcutaneously once daily, injected into the abdomen, and that is the only approved use PMID: 18057338PMID: 20554713. The visceral-fat phase 3 trials used exactly that, 2 mg/day for 26 weeks extended to 52, producing roughly 15-18% VAT reduction maintained only while dosing continued PMID: 20554713PMID: 18690162. The 12-month NAFLD study used the same 2 mg/day PMID: 31611038. The cognition trials used a lower 1 mg/day, self-administered about 30 minutes before bedtime, for 20 weeks PMID: 22869065PMID: 23689947.

Now the community side, described so you understand the conversation, not as instructions.

On the community's own comparison threads: tesamorelin is generally framed as the FDA-approved, visceral-fat-specific, once-daily option with real human data, while CJC-1295 (especially the DAC version) gets described as a cheaper, longer-acting "lifestyle" GH-support peptide often stacked with a ghrelin mimetic like ipamorelin for sleep and recovery. Forum users frequently note tesamorelin has the strongest evidence base of the GHRH analogs, which matches the literature.

Safety, IGF-1, and the Honest Caveats

Tesamorelin is a prescription drug approved only for HIV-associated lipodystrophy. Any other use, and any use of gray-market research peptide, is off-label or research-use-only and belongs in a conversation with a qualified clinician.

Trial-documented adverse events include injection-site reactions, arthralgia (joint pain), myalgia, peripheral edema and fluid retention, paresthesia (tingling, sometimes carpal-tunnel-like), and headache PMID: 21668043PMID: 20554713. Community reports mirror that list closely, and describe results as slow, usually over a couple of months, and reversing after stopping, which lines up with the trial finding that VAT re-accumulates off-drug PMID: 18690162.

On glucose: across the HIV trials, tesamorelin did not cause clinically meaningful changes in glucose or HbA1c at the group level PMID: 20554713PMID: 31611038. But it raises GH and IGF-1, which can reduce insulin sensitivity, so anyone with prediabetes or diabetes warrants glucose monitoring, and responder data show glucose homeostasis held up better in those who lost more visceral fat PMID: 22495074.

IGF-1 elevation is the intended effect and the main watch-item. Elevated IGF-1 is a theoretical growth-promoting concern; tesamorelin is contraindicated in active malignancy, in disruption of the hypothalamic-pituitary axis (pituitary tumor, surgery, radiation, head trauma), and should be avoided in pregnancy. IGF-1 is typically monitored, with dose reduction or discontinuation if it runs too high PMID: 21668043.

Lab Handling for Research Material

This is descriptive of research practice, not an endorsement of non-prescription use. Tesamorelin ships as a lyophilized (freeze-dried) powder. It gets reconstituted with bacteriostatic or sterile water, and once reconstituted it needs to stay cold, refrigerated at roughly 2-8C, and protected from light. Unreconstituted powder is more stable but is still best kept cool.

If you are handling research material, the two guides worth reading first are the complete peptide reconstitution guide and the peptide storage guide. Community discussion widely acknowledges that most non-prescription "tesamorelin" is gray-market peptide of unverified purity, which makes third-party testing non-optional. Learn to read a peptide COA and check independent vendor scorecards before trusting any lot.

Where To Get Research-Grade Tesamorelin

If you are sourcing research material, buy from a vendor that publishes a certificate of analysis per lot and makes it easy to verify. One option BodyHackGuide features is BHG Labs BHG-2T 10mg (Tesamorelin), currently in stock, with COA-per-lot testing. Reader code REDDIT takes 10% off.

*Independent vendor; BodyHackGuide may earn a commission. BHG Labs (bhglabs.co) is a separate third-party company, not BodyHackGuide.* Treat it as one reputable COA-backed option among several, not the only one. Verify the COA yourself and compare against the vendor scorecard before you buy.

For more on the compound and how it stacks, see the tesamorelin compound page and the retatrutide + tesamorelin shred stack protocol.

No comments yet — be the first to share your thoughts!

Related Articles